PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 9/20, 9/22, 9/52, 31/44, 31/41

A1

(11) International Publication Number: **WO 99/32091**

(43) International Publication Date: 1 July 1999 (01.07.99)

(21) International Application Number: PCT/SE98/02368

(22) International Filing Date: 17 December 1998 (17.12.98)

(30) Priority Data:
9704869-8 22 December 1997 (22.12.97) SE

(71) Applicant *(for all designated States except US)*: ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: KAREHILL, Per-Gunnar [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). LUNDBERG, Per, Johan [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE).

(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ORAL PHARMACEUTICAL EXTENDED RELEASE DOSAGE FORM

(57) Abstract

An enteric coated pharmaceutical extended release dosage form of an H^+,K^+-ATPase inhibitor giving an extended plasma concentration profile of an H^+,K^+-ATPase inhibitor. The extended plasma profile is obtained by a pharmaceutical composition which comprises a core material of a hydrophilic or hydrophobic matrix, and the H^+,K^+-ATPase inhibitor and optionally pharmaceutically acceptable excipients. The dosage form may be administered once daily.